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Abstract
Background: Invasive lobular carcinoma (ILC) accounts for 10–15% of primary breast cancers and is typically
estrogen receptor alpha positive (ER+) and ERBB2 non-amplified. Somatic mutations in ERBB2/3 are emerging as a
tractable mechanism underlying enhanced human epidermal growth factor 2 (HER2) activity. We tested the
hypothesis that therapeutically targetable ERBB2/3 mutations in primary ILC of the breast associate with poor
survival outcome in large public datasets.
Methods: We performed in silico comparison of ERBB2 non-amplified cases of ER+ stage I–III primary ILC (N = 279)
and invasive ductal carcinoma (IDC, N = 1301) using METABRIC, TCGA, and MSK-IMPACT information. Activating
mutations amenable to HER2-directed therapy with neratinib were identified using existing functional data from
in vitro cell line and xenograft experiments. Multivariate analysis of 10-year overall survival (OS) with tumor size,
grade, and lymph node status was performed using a Cox regression model. Differential gene expression analyses
by ERBB2 mutation and amplification status was performed using weighted average differences and an in silico
model of response to neratinib derived from breast cancer cell lines.
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Results: ILC tumors comprised 17.7% of all cases in the dataset but accounted for 47.1% of ERBB2-mutated cases.
Mutations in ERBB2 were enriched in ILC vs. IDC cases (5.7%, N = 16 vs. 1.4%, N = 18, p < 0.0001) and clustered in the
tyrosine kinase domain of HER2. ERBB3 mutations were not enriched in ILC (1.1%, N = 3 vs. 1.8%, N = 23; p = 0.604).
Median OS for patients with ERBB2-mutant ILC tumors was 66 months vs. 211 months for ERBB2 wild-type (p =
0.0001), and 159 vs. 166 months (p = 0.733) for IDC tumors. Targetable ERBB2 mutational status was an independent
prognostic marker of 10-year OS—but only in ILC (hazard ratio, HR = 3.7, 95% CI 1.2–11.0; p = 0.021). Findings were
validated using a novel ERBB2 mutation gene enrichment score (HR for 10-year OS in ILC = 2.3, 95% CI 1.04–5.05;
p = 0.040).
Conclusions: Targetable ERBB2 mutations are enriched in primary ILC and their detection represents an actionable
strategy with the potential to improve patient outcomes. Biomarker-led clinical trials of adjuvant HER-targeted
therapy are warranted for patients with ERBB2-mutated primary ILC.
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Background
Invasive lobular carcinoma of the breast (ILC) accounts
for 10–15% of all breast cancer with an estimated 250,
000 cases per year worldwide [1–4]. Nearly all cases of
ILC derive from luminal cells that express estrogen re-
ceptor alpha but lack E-Cadherin (CDH1) expression or
ERBB2 amplification [5].
Clinical evidence suggests that despite favorable
prognostic indicators, e.g., ER+ and/or progesterone
receptor positive, low Ki67 proliferation index and
HER2− status, patients with ILC have similar or
worse long-term outcomes compared to those with
invasive ductal carcinoma (IDC, otherwise known as
invasive carcinoma of no special type) [5, 6]. Adjuvant
treatment of ER+ ILC with letrozole, an aromatase in-
hibitor, may be superior to tamoxifen, and ILC cells
demonstrate resistance to tamoxifen in vitro [7, 8].
However, patients with ILC are treated according to
identical protocols as those with IDC [9, 10].
HER2-targeted therapy is indicated for patients whose
tumors are HER2+ by immunohistochemistry (IHC) or,
if IHC is equivocal, where ERBB2 is amplified as de-
tected by in situ hybridization (ISH) [11, 12]. Recent evi-
dence indicates that in ERBB2 non-amplified breast
cancer, somatic mutation of ERBB2 (ERBB2mut) and/or
ERBB3 (ERBB3mut) may provide an alternative mechan-
ism for upregulation of HER2 activity that is therapeut-
ically tractable using second generation HER2 tyrosine
kinase inhibitors such as neratinib [13, 14].
The epidermal growth factor (EGF) family of receptor
tyrosine kinases (HER1–4) are activated by ligand-
dependent homo-/heterodimerisation and regulate cellu-
lar proliferation and tumor progression [15, 16]. In
ERBB2-amplified cells, the oncogenic effect of HER2 is
mediated by heterodimerisation with HER3 in a ligand-
independent manner [17]. Thus HER3 is necessary for
HER2 oncogenic activity, and both HER2 and HER3 are
therapeutic targets in ERBB2-amplified breast cancer
[18]. Mutations in ERBB2 cluster in the tyrosine kinase
and extra-cellular domains of HER2 and exert their
oncogenic effects by activating tyrosine kinase activity or
increasing HER2 dimerization, respectively [13]. In vitro
studies of HER2 activity in cell line and xenograft
models identified 13 mutations (listed in the “Patients
and methods” section) that enhanced proliferation and/
or demonstrated growth inhibition with the irreversible
HER2/EGFR tyrosine kinase inhibitor, neratinib [13].
Mutations in HER3, a critical binding partner for HER2,
have been shown to promote ligand (EGF)-independent
transformation of breast epithelial cells only in the pres-
ence of kinase-active HER2 [19]. This indicates that
known oncogenic mutations in ERBB3, e.g., G284R and
E928G, may also be therapeutically targetable via HER2
inhibition [19].
ERBB2 mutations have previously been linked with
worse prognosis in CDH1-altered ILC: a study of ILC
cases in the TCGA dataset (N = 169) found that ERBB2
mutations (N = 6) occurred exclusively in CDH1-altered
tumors (N = 100) [20]. However, prognostic data on the
6 ERBB2mut cases were limited to 2 patient events for
both disease-free survival and OS analyses. The overall
rate of ERBB2mut in this study of primary ILC was 3.6%
(N = 6 out of 169). A study of relapsed CDH1-mutated
ILC found ERBB2mut in 18% of cases (N = 4 of 22), sug-
gesting further acquisition of ERBB2 mutations in
CDH1-altered ILC due to the selective pressure of treat-
ment [21].
To demonstrate the potential clinical benefit of target-
ing low frequency somatic mutations, prognostic ana-
lyses using large clinical datasets are required. In the
MA12 trial comprising 328 premenopausal patients with
ER+ primary breast cancer of all histological subtypes,
non-silent ERBB2 mutations occurred in 5.2% of patients
(N = 17) and were adversely prognostic of OS (p =
0.0114) [22]. A study of 5605 cases of relapsed breast
cancer found ERBB2mut in 2.4% of cases (N = 138), of
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which 20% (N = 27 of 138) were in ILC tumors [23].
However, neither of these larger studies stratified clinical
outcome by histological subtype.
An ILC-specific study of 630 cases of primary ILC
found ERBB2 and ERBB3 mutations in 5.1 and 3.6% of
tumors, respectively [24]. Comparison of cases of ER+,
HER2− ILC from the same study (N = 371) with cases of
ER+, HER2− IDC from TCGA (N = 338) indicated sig-
nificant enrichment of both ERBB2 and ERBB3 muta-
tions in ILC (4.3 and 3.5% in ILC vs. 1.5 and 0.6% in
IDC) [24]. The study reported limited statistical evidence
of a time-dependent effect of ERBB2 mutational status
associated with short-term breast cancer-specific sur-
vival. However, confirmation in datasets including pa-
tients with long-term follow-up and decoupling of
activating from silent mutations is needed.
We hypothesized that low-frequency somatic muta-
tions in ERBB2 and ERBB3 are enriched in ER+, ERBB2
non-amplified primary ILC cases and may have a dem-
onstrable prognostic effect. We tested these hypotheses
by mining a combined dataset of the three largest pri-
mary breast cancer series with data on tumor ERBB2
and ERBB3 mutational status, gene expression, clinico-
pathological features, and patient survival outcomes.
Our overall goal was to determine the association be-
tween targetable ERBB2/3 mutations and survival in pri-
mary ER+ ILC, and thereby provide evidence for a
clinically actionable strategy to improve patient
outcomes.
Patients and methods
Patients and outcome measures
Genomic and clinical outcome data associated with
tumor samples from patients with primary breast cancer
in TCGA 2015 (N = 817), METABRIC 2012 and 2016
(N = 2509), and MSK-IMPACT 2018 (N = 918) were
accessed online via CBioportal [25–27]. From these data-
sets, ER+ and HER2− cases of stage I–III ILC and IDC
with both clinical outcome and mutational data called
from next-generation sequencing (NGS) analyses were
selected (N = 1580). Cases of mixed or non-ILC/IDC
histology, ER-negative/undetermined, HER2+/undeter-
mined, carcinoma in situ, and stage 4/undetermined
were excluded. For TCGA and MSK datasets, HER2 sta-
tus was determined by IHC (positive/negative) or, where
IHC was indeterminate, by ISH assessment of ERBB2
amplification, in line with standard clinical practice [11].
For METABRIC cases, HER2 status was determined
using the Affymetrix SNP6 copy number inference
pipeline.
The primary outcome measure, available in all data-
sets, was OS. Variables included ERBB2 and ERBB3 mu-
tational status. ERBB2mut status was subcategorized as
oncogenic or uncharacterized by cross-reference with
existing data that identified mutations targetable by
HER2-inhibition: G309A/E, S310F, L755S, del755-759,
S760A, D769H, D769Y, V777L, P780ins, V842I, and
R896C [13]. Cases were denominated oncERBB2mut if tu-
mors harbored at least one oncogenic ERBB2 mutation.
Clinical and NGS mutation data were integrated with
clinicopathological features including histological sub-
type, lymph node (LN) status, and tumor size and grade.
Normalized gene expression data were publicly available
for METABRIC (Illumina HT12 microarray) and TCGA
(RNA-seq) datasets.
Statistical analysis
For analysis of binary somatic mutation status, combined
cohort analysis was performed. Enrichment for cases
with mutations in candidate genes (ERBB2/3mut) by
histological subtype (ILC vs. IDC) was determined by χ2
test for association between categorical variables. For
ILC and IDC separately, Kaplan-Meier (KM) survival
curves stratified by mutation status were compared
using logrank and generalized Wilcoxon tests. Multivari-
ate analysis of OS was performed using a Cox regression
model. Covariates included classic prognostic markers
tumor grade, size (< 20mm or ≥ 20 mm), and LN status
(positive or negative). Adjustment was made for age at
diagnosis (< 50 or ≥ 50 years). Tumor grade was classified
as low (grade 1–2) or high (grade 3).
To derive a novel gene expression signature of HER2
activity that accounted for the effect of potentially tar-
getable ERBB2mut in ERBB2 non-amplified tumors, we
applied a weighted average difference (WAD) method to
gene expression data in cases from the METABRIC 2012
(N = 1980) and TCGA 2015 (N = 817) cohorts [25, 28,
29]. Gene expression in ERBB2mut cases (N = 38, se-
lected by ERBB2 non-amplified status and patient age >
50) was compared with the same order of magnitude of
ERBB2 wild-type cases (N = 79, selected by ERBB2 non-
amplified status, grade > 1, stage > I, patient age > 50).
This was repeated for oncERBB2mut cases (N = 23)
using the same comparator and selection criteria. To in-
corporate the effect of HER2 activity via ERBB2 amplifi-
cation, the overlap of differentially expressed genes
DEGs shared by both comparisons (ERBB2mut and
oncERBB2mut vs. ERBB2 wild-type) with DEGs from a
further comparison of ERBB2 amplified (N = 247) vs.
non-amplified (N = 1733) cases in METABRIC was cal-
culated. Finally, to incorporate the downstream pheno-
type (HER2 status), the overlap of this list with DEGs
from a comparison of clinical HER2+ vs. HER2− cases
in TCGA was calculated. In contrast to ERBB2mut
cases, matching was not performed for ERBB2 amplified
or HER2+ cases because numbers were higher and
within an order of magnitude across groups, such that
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similar variation in gene expression could reasonably be
assumed.
Multiple gene expression signatures of HER2 activity
have been derived using cell line models and patient tumors
[30–33]. We compared our novel gene signature with the
HER2 activity signature established by Desmedt et al [31]
with respect to its ability to detect potentially targetable
ERBB2mut cases in our ILC/IDC dataset. This was
achieved by multivariate regression modeling of response
to neratinib for each gene signature using breast cancer cell
line pharmacogenomic data from the BROAD Institute,
accessed online via the CellMinerCDB portal [34, 35]. The
Pearson coefficient for each significantly correlated signa-
ture gene was used to calculate normalized signature scores
for each METABRIC case in the current dataset. To valid-
ate the prognostic effect of ERBB2 in ILC, cases were then
stratified by gene signature score (upper vs. lower quartiles)
and the signatures compared by histological subtype using
a Cox regression model of a 10-year OS.
Results
Clinicopathological landscape of the combined cohort
All cases of primary (stage I–III) ER+ and HER2−
ILC and IDC from METABRIC, TCGA, and MSK-
IMPACT cohorts were selected (total N = 1580, see
Table 1). Baseline clinicopathological characteristics
by individual cohort are summarized in Table 1.
To detect prognostic effects of low-frequency muta-
tions and add to the existing body of literature on ILC-
specific mutational drivers, a combined cohort of three
public datasets was collated. We first evaluated the im-
plications of combining cases of ILC and IDC from po-
tentially disparate datasets.
In the combined cohort, long-term follow-up of pa-
tients is dominated by the largest dataset (METABRIC,
N = 702: mean follow-up 133 months) while early events
are enriched by the two smaller datasets (TCGA and
MSK, N = 878: mean follow-up 33months) (see Supple-
mental Figure S1(A) in Additional file 1 for KM plot).
Compared to the smaller datasets with shorter follow-up
(TCGA and MSK), patients in METABRIC were more
likely to be over 50 years of age and have T1 tumors (<
20mm diameter), but no significant difference in grade
or LN status was found (see Table 2). As the principle
skew in the combined dataset is towards longer follow-
up in METABRIC cases, OS analysis was limited to 10
years—thus providing a clinically meaningful endpoint
for all patients, irrespective of age. Comparison of
Table 1 Baseline clinicopathological characteristics of the combined cohort
METABRIC (N = 702) TCGA (N = 330) MSK-IMPACT (N = 548) Total (N = 1580)
N % N % N % N %
Histology* ILC 76 10.8 100 30.3 103 18.8 279 17.7
IDC 626 89.2 230 69.7 445 81.2 1301 82.3
Age < 50 years 125 17.8 87 26.4 190 34.7 402 25.4
≥ 50 years 577 82.2 243 73.6 358 65.3 1178 74.6
Menopause Pre- 125 17.8 90 27.2 234 42.7 449 28.5
Post- 577 82.2 219 66.4 309 56.4 1105 69.9
unknown 0 0 21 6.4 5 0.9 26 1.6
Stage* I 238 33.9 67 49.3 270 49.3 575 36.4
II 418 59.5 188 34.3 188 34.3 794 50.3
III 46 6.6 75 16.4 90 16.4 211 13.4
Tumor size < 20 mm 215 30.6 96 29.1 330 60.2 641 40.6
≥ 20mm 487 69.4 234 70.9 218 39.8 939 59.4
Tumor grade 1 61 8.7 49 14.8 51 9.3 161 10.2
2 344 49.0 190 57.6 191 34.9 725 45.9
3 268 38.2 81 24.5 288 52.6 637 40.3
Unknown 29 4.1 10 3.0 18 3.3 57 3.6
Follow-up < 5 years 137 19.5 261 82.8 454 82.8 852 53.9
5–10 years 195 27.8 61 11.7 64 11.7 320 20.3
≥ 10 years 370 52.7 8 5.5 30 5.5 408 25.8
Status Alive** 310 44.2 299 90.1 494 90.1 1103 69.8
Deceased 392 55.8 31 9.9 54 9.9 477 20.3
*Cases of ILC/IDC histology, stage I–III, ER+ and HER2− status with clinical outcome and mutational data were selected via CBioportal
**At last follow-up
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METABRIC with combined TCGA and MSK-IMPACT
cohorts revealed no significant difference in a 10-year
OS (logrank p = 0.225, see Supplemental Figure S1(B) in
Additional file 1).
ERBB2 mutations are enriched in primary ILC and cluster
in the HER2 tyrosine kinase domain
We next assessed the prevalence of ERBB2/3mut in our
dataset of ILC and IDC (N = 1580). Overall prevalence of
ERBB2mut was 2.2% (N = 34). ERBB2mut was enriched
in ILC, with prevalence of 5.7% (N = 16) vs. 1.4% in IDC
(N = 18) (p < 0.0001). In contrast, prevalence of ERBB3-
mut was lower (1.6% overall, N = 26), and there was no
enrichment of ERBB3mut in ILC vs. IDC (1.1%, N = 3 vs.
1.8%, N = 23; p = 0.604). Due to the small number of
cases in ILC, further analysis of ERBB3mut was not
performed.
In ILC, ERBB2mut clustered in the tyrosine kinase do-
main of HER2 (15 out of 16 cases; 93.8%). Of these, the
majority have been characterized as oncogenic and poten-
tially targetable using neratinib (oncERBB2mut, 11 out of
15 kinase domain mutations in ILC; 73.3%). In IDC, all
kinase domain mutations were known oncogenic (N = 8)
and non-characterized mutations were distributed evenly
across protein domains (see Fig. 1). The most frequently
occurring ERBB3mut coded for E928G, which lies in the
tyrosine kinase domain of HER3 (N = 7 out of 26; 27%).
ERBB2 mutation is an adverse prognostic indicator of
survival for patients with primary ILC
Using our meta-cohort of 1580 cases, we next assessed
ERBB2mut as a prognostic marker of OS in ILC (N =
279) and IDC (N = 1301). Median duration of patient
follow-up was 50months (range 0–351 months). In pa-
tients with ILC, median OS was significantly shorter if
tumors were ERBB2mut positive (inclusive of oncogenic
and uncharacterized mutations) vs. ERBB2mut negative
(66 vs. 211 months, p = 0.0001). In contrast, there was
no significant difference in OS for ERBB2mut cases of
IDC (159 vs. 166months, p = 0.733) (see Fig. 2).
ERBB3mut status was not a significant prognostic indi-
cator of OS in cases of IDC (HR = 1.46, 95% CI 0.65–
3.28; p = 0.359). There were no events (patient deaths) at
10 years of follow-up in the three cases of ERBB3mut
ILC.
Targetable ERBB2 mutation status is an independent
adverse prognostic marker of 10-year overall survival in
ER+, ERBB2 non-amplified ILC
To test the effect of therapeutically actionable ERBB2
mutations on a clinically relevant endpoint, we stratified
10-year OS by oncERBB2mut status. In ER+, ERBB2
non-amplified ILC, oncERBB2mut status was prognostic
of 10-year OS independently of LN status, tumor grade,
and size (HR 3.65, 95% CI 1.21–11.00; p = 0.021, see
Fig. 3). The independent prognostic value of oncERBB-
mut status on 10-year OS was retained after further
adjusting for age at diagnosis (HR 3.19, 95% CI 1.06–
9.62; p = 0.039).
Unselected ERBB2mut status (including oncogenic and
uncharacterized mutations) was also adversely prognostic
of 10-year OS in univariate analysis (HR 3.66, 95% CI 1.54–
8.73; p = 0.003), but in contrast to characterized oncERBB2-
mut, this prognostic effect was not independent of LN
stage, tumor grade, and/or size. The independent prognos-
tic value of oncERBB2mut was further verified at 5 years of
follow-up (HR 3.668, 95% CI 1.096–12.275; p = 0.035).
A novel gene signature of targetable HER2 activity using
ERBB2mut status
Since existing gene signatures of HER activity derive
from HER2 status (by IHC and/or ISH), we generated a
novel gene signature incorporating DEGs in ERBB2mut
and oncERBB2mut cases, as described in the “Patients
and methods” section and outlined in Fig. 4. Our aim
was to establish a novel signature that reflects HER2
Table 2 Comparison of long vs. short follow-up cohorts: METABRIC (largest dataset, long follow-up) vs. TCGA and MSK (combined
smaller datasets, short follow-up). Significant difference was found with respect to age and tumor size, but not tumor grade or LN
status. Table excludes “unknown” cases for each variable
METABRIC (N = 702) TCGA AND MSK (N = 878) χ2 test
N % N %
Age < 50 years 125 17.8 277 31.5 p < 0.00001
≥ 50 years 577 82.2 601 68.5
Tumor size < 20mm 215 30.6 426 48.5 p < 0.00001
≥ 20 mm 487 69.4 452 51.5
Tumor grade 1–2 405 60.2 481 56.6 p = 0.158
3 268 39.8 369 43.4
LN status Negative 370 53.9 489 55.8 p = 0.457
Positive 316 46.1 387 44.2
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pathway activity more completely than existing signa-
tures, whether induced by ERBB2 mutations or amplifi-
cations, and to be able to apply it in a wider range of
patients. A list of up and downregulated ERBB2 “mu-
tant” DEGs (N = 20) was generated by combining the
overlap between DEGs for METABRIC ERBB2 amplified
vs. non-amplified, ERBB2 mutated vs. wild-type (ERBB2-
mut and oncERBB2mut separately), and TCGA HER2+
vs. HER2− (Fig. 4a, and see Additional file 2 for Supple-
mental Tables S1–3 with all gene lists).
As shown in Fig. 4b, ERBB2mut and oncERBB2mut
clustered in the upper quartile of the novel gene signa-
ture score in cases of ER+, HER2− ILC/IDC from
METABRIC. In contrast, ERBB2mut and oncERBB2mut
cases did not cluster when scored by the established
gene signature of HER2 pathway activation but were
evenly distributed across the cohort. Both the novel and
established HER2 pathway gene signatures were predict-
ive of response to neratinib in multivariate analysis using
a pharmacogenomic breast cancer cell line model
Fig. 1 Rate of ERBB2 and ERBB3 mutations and their spatial distribution on HER2/3 in ILC and IDC. ERBB2mut were found to be a enriched in ILC
(yellow bar) vs. IDC (blue bar) and b clustered in the tyrosine kinase domain of HER2; c ERBB3mut occurred at lower frequency, with the high-
frequency outlier in IDC coding for known oncogenic HER3 kinase domain alteration E928G (N = 6). Y-axes show the number of cases harboring
at least one ERBB2/3 mutation at a specific amino acid (aa) of HER2/3, shown along the x-axes. Yellow-filled circles indicate oncERBB2mut.
Extracellular domains of HER2/3: Receptor L, Furin-like and Growth Factor Receptor IV; intracellular: tyrosine protein kinase. *p < 0.001;
n/s = not significant
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(Pearson R = 0.9, p < 1e−14 for both; see Supplemental
Figure S2 in Additional file 3 for the original plots from
the CellMinerCDB online portal). The regression model
used incorporates drug response and gene expression
data from N = 36 breast cancer cell lines [35, 36]. Our
findings using this model verify that the novel signature
derived from DEGs in ERBB2mut vs. wild-type cases in-
corporates oncogenic HER2 activity due to ERBB2mut.
This suggests that a gene signature may have value in
predicting targetable ERBB2 alterations including
ERBB2mut in HER2− breast cancer. Finally, Fig. 4c dem-
onstrates that the novel gene signature score (stratified
into upper vs. lower quartiles) was adversely associated
with 10-year OS (HR = 2.3, 95% CI 1.04–5.05; p = 0.040),
thus providing mRNA level validation of ERBB2mut as
an adverse prognostic marker.
Using the same dataset (CellMinerCDB), it was not
possible to associate ERBB2mut status with neratinib
response as only one breast cancer cell line (MDA-MB-
468) was ERBB2mut positive. Response to neratinib for
MDA-MB-468 was in the upper tertile of breast cancer
cell lines (data in the public domain via CellMinerCDB
online portal).
Discussion
In this study, we mined clinical and NGS data from the
largest clinical cohorts with data in the public domain to
test whether there was an ILC-specific association of
ERBB2 mutations with OS. In our meta-cohort of ER+,
ERBB2 non-amplified cases of ILC and IDC, we found
that ERBB2 mutations are enriched ILC, cluster in the
functional kinase domain of HER2, and robustly associ-
ate with adverse clinical outcomes—independently of
known prognostic clinicopathological features including
LN status and tumor grade. In contrast, there was no
ILC-specific enrichment of ERBB3mut.
Fig. 2 OS by ERBB2 mutational status in ILC (left) and IDC (right). Gray line indicates ERBB2 wild-type cases; blue line indicates cases with at least
one ERBB2mut
Fig. 3 Univariate and multivariate analyses of 10-year OS in N = 279 cases of ER+, ERBB2 non-amplified ILC. Gray square dot indicates hazard ratio
(HR) in univariate analysis and the gray bar indicates the 95% confidence interval (CI). Significant prognostic variables in univariate analyses
(where 95% CI does not span HR = 1) are included in multivariate analysis, shown in blue. For each variable, cases with unknown values are
excluded from the analysis
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Fig. 4 A novel gene signature of HER2 activity incorporating ERBB2mut, ERBB2 amplification, and clinical HER2 status. a Generation of a 20-gene
signature of HER2 activity. The upper Venn diagrams show the overlap between the top 500 DEGs by WAD score for METABRIC amplified vs.
non-amplified, ERBB2 mutant vs. wild-type, and TCGA HER2+ vs. HER2−. Upregulated DEGs are shaded blue and down-regulated DEGs yellow.
ERBB2mut and oncERBB2mut vs. wild-type are analyzed separately, and the overlap combined in the lower Venn diagrams. b Comparison with an
established 24-gene signature of HER pathway activation [31], using a gene signature (genesig) score derived from multivariate analysis of
response to neratinib in breast cancer cell lines. Cases with ERBB2mut (gray lines) and oncERBB2mut (blue lines) clustered in the upper quartile of
normalized genesig scores for the novel signature but not the established signature. c 10-year OS analysis of cases in the current study stratified
by histological subtype and novel genesig score (upper vs. lower quartiles) indicates that ERBB2mut-associated DEGs are prognostic in ILC but not
IDC. GE, geneset enrichment
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Compared to the largest previous study with data
on ERBB2 mutational status in primary ILC (N = 371)
[24], the current study found higher frequency of
ERBB2mut (5.7 vs. 4.3%) but lower frequency of
ERBB3mut (1.1 vs. 3.5%). Hazard proportionality in
the study by Desmedt et al 2016 suggested that
ERBB2 mutational status had a time-dependent effect
associated with short-term risk of breast cancer re-
lapse [24]. The current study adds data on the prog-
nostic effect of specific ERBB2 mutations that were
previously shown in cell line, in vitro and xenograft
studies to respond to existing clinical compounds
such as trastuzumab or neratinib [13]. We demon-
strated that the status of these therapeutically target-
able ERBB2 mutations is an independent adverse
prognostic marker of overall survival in a large cohort
of patients with ILC.
Findings from the current study imply that targeted
sequencing of ILC tumors for ERBB2 mutations may
be an actionable and viable strategy to improve out-
comes for patients with primary ILC by providing a
biomarker for HER2-targeted therapy in the adjuvant
setting. Based on worldwide ILC incidence of 250,000
[1–4], 10% rate of ER− and/or HER2− status in ILC,
and 5% rate of potentially targetable ERBB2mut in
ER+, ERBB2 non-amplified ILC, we conservatively es-
timate that 11,250 additional ILC patients per year
who have ERBB2-mutated tumors may benefit from
HER2-targeting therapy.
Existing clinical studies of HER2-targeting therapy
are underway in advanced breast cancer. For example,
neratinib (alone or in combination with fulvestrant)
was tested in phase II study for patients with ad-
vanced, ERBB2 non-amplified, ERBB2mut breast can-
cer (clinical trial registration number NCT01670877).
Of the 16 patients who had evaluable tumor re-
sponses, N = 2 had partial response by RECIST cri-
teria (13%). Out of 14 patients with tumors harboring
oncERBB2mut, N = 5 (36%) derived clinical benefit,
defined as stable disease or partial/complete response
by RECIST criteria [37]. Given that the patients in
this trial had received multiple prior lines of treat-
ment, it is conceivable that patients with ERBB2 non-
amplified primary tumors harboring oncERBB2mut
will also derive benefit from (neo) adjuvant HER2-
targeted therapy such as neratinib.
In the current cohort of primary ER+, HER2− ILC
and IDC, ERBB2 mutations in ILC tumors clustered
almost exclusively in the active HER2 tyrosine kinase
domain (N = 15 of 16). Our retrospective clinical out-
come data indicates an ILC-specific adverse survival
association for patients with ERBB2 non-amplified tu-
mors harboring potentially targetable ERBB2 muta-
tions. This primary finding was validated by existing
mRNA data via a novel gene signature of HER2 activ-
ity, which linked ERBB2mut with response to nerati-
nib. Subject to independent external validation, a
gene signature of HER2 activity could have clinical
application as a biomarker of response to HER2-
targeted small molecules such as neratinib and may
be more cost-effective than targeted NGS in the de-
tection of ERBB2mut in primary ILC.
Taken together, these new findings suggest that focus-
ing early phase studies of HER2-inhibition (e.g., with
neratinib) in patients with ERBB2 non-amplified,
ERBB2mut primary ILC may be an effective strategy to
demonstrate feasibility and clinical benefit in the (neo)
adjuvant setting.
Limitations of the current study include cohort size,
quality of clinical outcome data, and bias in long-
term follow-up towards cases from the largest dataset
(METABRIC). Statistical power is limited by the small
number of patient deaths in cases of ILC and IDC
with ERBB2mut (N = 7 and 8, respectively). However,
the clear deviation of the KM plot of OS in ILC
stratified by ERBB2mut (Fig. 2) is reflected in a low
type I error of one in 10,000 (p = 0.0001). In contrast,
there was no ILC-specific enrichment of ERBB3mut
in our database. However, in IDC there was enrich-
ment of the known oncogenic HER3 kinase domain
mutation, E928G. To demonstrate the prognostic ef-
fect of mutations affecting HER3, larger datasets will
be required.
The effect of incomplete clinical outcome data on the
primary endpoint (OS) is difficult to quantify but is
accounted for statistically in Cox regression modeling
by censoring patients at last follow-up. Patients in
METABRIC presented at older age, which is associ-
ated with more indolent, less biologically aggressive
breast cancer [38]. This implies an underestimation of
the adverse impact of ERBB2 mutations on 10-year
survival outcomes in the current study. Since the
METABRIC dataset did not have complete HER2 IHC
or reverse-phase protein array data, it was not pos-
sible to associate activating ERBB2mut directly with
downstream HER2 protein expression. Instead, we
generated a gene signature incorporating clinical
HER2 status to validate our findings.
Conclusions
Targetable kinase domain ERBB2 mutations are enriched
in primary ILC and their detection by targeted sequen-
cing or validated gene signature surrogate may provide
an actionable strategy to improve patient outcomes.
Biomarker-led clinical trials of adjuvant HER2-targeted
therapy to treat breast tumors with activating ERBB2
mutations are warranted in HER2− primary ILC.
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wild-type (ERBB2mut) and oncERBB2mut vs. wild-type (oncERBB2mut), and
TCGA HER2+ vs. HER2- (TCGA HER2+).
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observed response of breast cancer cell lines (N = 36) to neratinib and
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generated using CellMinerCDB online portal and cell line data from the
BROAD Institute [34, 35].
Abbreviations
CI: Confidence interval; DEG: Differentially expressed gene; EGF: Epidermal
growth factor; ER: Estrogen receptor alpha; ERBB2/3mut: ERBB2/3 mutant;
HER2/3: Human epidermal growth factor receptor 2/3; HR: Hazard ratio;
IDC: Invasive ductal carcinoma of the breast; IHC: Immunohistochemistry;
ILC: Invasive lobular carcinoma of the breast; ISH: In situ hybridization;
KM: Kaplan-Meier; LN: Lymph node; NGS: Next-generation sequencing;
oncERBB2mut: Oncogenic ERBB2 mutant; OS: Overall survival; RECI





SK, DMH, WZ, SO, and SJJ conceived, designed, and supervised the study. SK,
MA, CM, KB, NPM, and SJJ analyzed and interpreted the data. SK, WZ, SO,
and SJJ prepared the manuscript. ARG, IOE, and EAR had supervisory and
administrative roles. SJ, TF, and KS had consultative roles in study design. All
authors were involved in manuscript preparation and reviewing for
submission, gave their final approval, and agreed to be accountable for all
aspects of the work.
Funding
The corresponding author (SJJ) is funded by the Wellcome Trust (Royal
Academy of Medical Sciences grant number AAM 127669) and the National
Institute for Health Research UK. Dr. Oesterreich’s work on ILC is supported
by the Breast Cancer Research Foundation and a Komen Scholar awards
(SAC160073).
Availability of data and materials
The datasets generated and/or analyzed during the current study are
available via the CBioportal online portal (http://www.cbioportal.org) and in
the Genome-Phenome Archives EGAS00000000098 and phs000178 (https://
ega-archive.org/studies/EGAS00000000098 and https://ega-archive.org/stud-
ies/phs000178).
Ethics approval and consent to participate
Ethics approvals and consent for each cohort (METABRIC, TCGA, and MSK-




Since the first submission of the article, the corresponding author (SJJ) has
moved employment to AstraZeneca, with no competing interests to declare.
All other authors declare that they have no competing interests.
Author details
1Nottingham Breast Cancer Research Centre, Nottingham Biodiscovery
Institute, School of Medicine, University of Nottingham, Nottingham, UK.
2Department of General Surgical Science, Gunma University Graduate School
of Medicine, Gunma, Japan. 3Department of Breast Surgery, International
University of Health and Welfare, Narita, Japan. 4School of Veterinary
Medicine and Science, University of Nottingham, Nottingham, UK. 5Gene
Regulation and RNA Biology Laboratory, School of Pharmacy, University of
Nottingham, Nottingham, UK. 6Division of Oncogenomics, Oncode Institute,
Netherlands Cancer Institute, Amsterdam, Netherlands. 7Womens Cancer
Research Center, UPMC Hillman Cancer Center and Magee-Women Research
Institute, Pittsburgh, PA, USA. 8Translational Medicine, Oncology Research
and Development, AstraZeneca, Darwin Building, Milton, Cambridge, UK.
Received: 21 January 2020 Accepted: 26 July 2020
References
1. Martinez V, Azzopardi JG. Invasive lobular carcinoma of the breast:
incidence and variants. Histopathology. 1979;3(6):467–88.
2. Li CI, Anderson BO, Daling JR, Moe RE. Trends in incidence rates of invasive
lobular and ductal breast carcinoma. JAMA. 2003;289(11):1421–4.
3. Li CI, Daling JR. Changes in breast cancer incidence rates in the United
States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer
Epidemiol Biomark Prev. 2007;16(12):2773–80.
4. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M,
et al. Estimating the global cancer incidence and mortality in 2018:
GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–53.
5. Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, et al.
Distinct clinical and prognostic features of infiltrating lobular carcinoma of
the breast: combined results of 15 International Breast Cancer Study Group
clinical trials. J Clin Oncol. 2008;26(18):3006–14.
6. Rakha EA, El-Sayed ME, Powe DG, Green AR, Habashy H, Grainge MJ, et al.
Invasive lobular carcinoma of the breast: response to hormonal therapy and
outcomes. Eur J Cancer. 2008;44(1):73–83.
7. Metzger Filho O, Giobbie-Hurder A, Mallon E, Gusterson B, Viale G, Winer EP,
et al. Relative effectiveness of letrozole compared with tamoxifen for
patients with lobular carcinoma in the BIG 1-98 trial. J Clin Oncol. 2015;
33(25):2772–9.
8. Sikora MJ, Cooper KL, Bahreini A, Luthra S, Wang G, Chandran UR, et al.
Invasive lobular carcinoma cell lines are characterized by unique estrogen-
mediated gene expression patterns and altered tamoxifen response. Cancer
Res. 2014;74(5):1463–74.
9. NICE. Early and locally advanced breast cancer: diagnosis and management.
Online: National Institute for Health and Care Excellence; 2018 [NICE
Pathway]. Available from: https://www.nice.org.uk/guidance/ng101.
10. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT,
et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis,
treatment and follow-updagger. Ann Oncol. 2019;30(8):1194–220.
11. Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS,
et al. Human epidermal growth factor receptor 2 testing in breast cancer:
American Society of Clinical Oncology/College of American Pathologists
Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36(20):2105–
22.
12. Denduluri N, Chavez-MacGregor M, Telli ML, Eisen A, Graff SL, Hassett MJ,
et al. Selection of optimal adjuvant chemotherapy and targeted therapy for
early breast Cancer: ASCO clinical practice guideline focused update. J Clin
Oncol. 2018;36(23):2433–43.
13. Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, et al.
Activating HER2 mutations in HER2 gene amplification negative breast
cancer. Cancer Discov. 2013;3(2):224–37.
14. Hanker A, Koch J, Ye D, Sliwoski G, Sheehan J, Kinch L, et al. Abstract PD3-
05: Co-occurring gain-of-function mutations in HER2 and HER3 cooperate to
enhance HER2/HER3 binding, HER-dependent signaling, and breast cancer
growth. Cancer Res. 2019;79(4 Supplement):PD3–05-PD3.
Kurozumi et al. Breast Cancer Research           (2020) 22:85 Page 10 of 11
15. Eroglu Z, Tagawa T, Somlo G. Human epidermal growth factor receptor
family-targeted therapies in the treatment of HER2-overexpressing breast
cancer. Oncologist. 2014;19(2):135–50.
16. Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer.
Curr Opin Cell Biol. 2009;21(2):177–84.
17. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS,
et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by
trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.
Cancer Cell. 2009;15(5):429–40.
18. Mishra R, Patel H, Alanazi S, Yuan L, Garrett JT. HER3 signaling and targeted
therapy in cancer. Oncol Rev. 2018;12(1):355.
19. Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, et al.
Oncogenic ERBB3 mutations in human cancers. Cancer Cell. 2013;23(5):603–
17.
20. Ping Z, Siegal GP, Harada S, Eltoum IE, Youssef M, Shen T, et al. ERBB2
mutation is associated with a worse prognosis in patients with CDH1
altered invasive lobular cancer of the breast. Oncotarget. 2016;7(49):80655–
63.
21. Ross JS, Wang K, Sheehan CE, Boguniewicz AB, Otto G, Downing SR, et al.
Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer
shows a high frequency of HER2 (ERBB2) gene mutations. Clin Cancer Res.
2013;19(10):2668–76.
22. Griffith OL, Spies NC, Anurag M, Griffith M, Luo J, Tu D, et al. The prognostic
effects of somatic mutations in ER-positive breast cancer. Nat Commun.
2018;9(1):3476.
23. Ross JS, Gay LM, Wang K, Ali SM, Chumsri S, Elvin JA, et al. Nonamplification
ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast
cancer: an emerging opportunity for anti-HER2 targeted therapies. Cancer.
2016;122(17):2654–62.
24. Desmedt C, Zoppoli G, Gundem G, Pruneri G, Larsimont D, Fornili M, et al.
Genomic characterization of primary invasive lobular breast cancer. J Clin
Oncol. 2016;34(16):1872–81.
25. Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, et al.
Comprehensive molecular portraits of invasive lobular breast cancer. Cell.
2015;163(2):506–19.
26. Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA, et al.
The somatic mutation profiles of 2,433 breast cancers refines their genomic
and transcriptomic landscapes. Nat Commun. 2016;7:11479.
27. Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, et al. The
genomic landscape of endocrine-resistant advanced breast cancers. Cancer
Cell. 2018;34(3):427–38 e6.
28. Kadota K, Nakai Y, Shimizu K. A weighted average difference method for
detecting differentially expressed genes from microarray data. Algorithms
Mol Biol. 2008;3:8.
29. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The
genomic and transcriptomic architecture of 2,000 breast tumours reveals
novel subgroups. Nature. 2012;486(7403):346–52.
30. Ferrari A, Vincent-Salomon A, Pivot X, Sertier AS, Thomas E, Tonon L, et al. A
whole-genome sequence and transcriptome perspective on HER2-positive
breast cancers. Nat Commun. 2016;7:12222.
31. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G,
et al. Biological processes associated with breast cancer clinical outcome
depend on the molecular subtypes. Clin Cancer Res. 2008;14(16):5158–65.
32. Sareyeldin RM, Gupta I, Al-Hashimi I, Al-Thawadi HA, Al Farsi HF, Vranic S,
et al. Gene expression and miRNAs profiling: function and regulation in
human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
Cancers (Basel). 2019;11(5):646.
33. Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D.
Activation of mitogen-activated protein kinase in estrogen receptor alpha-
positive breast cancer cells in vitro induces an in vivo molecular phenotype
of estrogen receptor alpha-negative human breast tumors. Cancer Res.
2006;66(7):3903–11.
34. Rees MG, Seashore-Ludlow B, Cheah JH, Adams DJ, Price EV, Gill S, et al.
Correlating chemical sensitivity and basal gene expression reveals
mechanism of action. Nat Chem Biol. 2016;12(2):109–16.
35. Rajapakse VN, Luna A, Yamade M, Loman L, Varma S, Sunshine M, et al.
CellMinerCDB for integrative cross-database genomics and
pharmacogenomics analyses of cancer cell lines. iScience. 2018;10:247–64.
36. Basu A, Bodycombe NE, Cheah JH, Price EV, Liu K, Schaefer GI, et al. An
interactive resource to identify cancer genetic and lineage dependencies
targeted by small molecules. Cell. 2013;154(5):1151–61.
37. Ma CX, Bose R, Gao F, Freedman RA, Pegram MD, Blackwell K, et al. Phase II
trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer
(HER2(mut) MBC). J Clin Oncol. 2016;34(15 suppl):516.
38. Syed BM, Green AR, Paish EC, Soria D, Garibaldi J, Morgan L, et al. Biology of
primary breast cancer in older women treated by surgery: with correlation
with long-term clinical outcome and comparison with their younger
counterparts. Br J Cancer. 2013;108(5):1042–51.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Kurozumi et al. Breast Cancer Research           (2020) 22:85 Page 11 of 11
